According to TipRanks.com, Belanger is a 4-star analyst with an average return of 6.8% and a 48.0% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and Collegium Pharmaceutical.
Akebia Therapeutics has an analyst consensus of Hold, with a price target consensus of $2.00, representing a 251.2% upside. In a report issued on March 30, Piper Sandler also downgraded the stock to Hold with a $2.00 price target.
Akebia Therapeutics’ market cap is currently $103.4M and has a P/E ratio of -0.33.
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AKBA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Read More on AKBA:
- Apple: Skating to Where the Puck is Headed
- Oppenheimer Sees Gains of Over 100% in These 3 Beaten-Down Stocks
- Maxim Group Sticks to Its Buy Rating for Citius Pharmaceuticals (CTXR)
- Analysts’ Top Consumer Goods Picks: Lamb Weston Holdings (LW), Compagnie Générale des Établissements Michelin (MGDDF)
- Is Zelle a Threat to Visa & Mastercard?